- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | HCW Biologics Inc.: HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum | 1 | GlobeNewswire (USA) | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 30.04. | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.04. | HCW Biologics plant IND-Antrag für Krebsmedikament trotz hoher Barmittelverbrennung | 1 | Investing.com Deutsch | ||
| 27.04. | HCW Biologics plans 2027 IND filing for pancreatic cancer drug | 1 | Investing.com | ||
| 27.04. | HCW Biologics Inc.: HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors | 151 | GlobeNewswire (Europe) | Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in... ► Artikel lesen | |
| 24.04. | HCW Biologics Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 23.04. | HCW Biologics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 16.04. | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | HCW Biologics reports Q4 results | 1 | Seeking Alpha | ||
| 31.03. | HCW Biologics Inc.: HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results | 158 | GlobeNewswire (Europe) | MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion... ► Artikel lesen | |
| 31.03. | HCW Biologics Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.03. | HCW Biologics receives $7M upfront fee from China licensee | 1 | Investing.com | ||
| 17.03. | HCW Biologics erhält 7 Millionen US-Dollar Vorauszahlung von Lizenznehmer aus China | 10 | Investing.com Deutsch | ||
| 17.03. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | HCW Biologics Inc.: HCW Biologics Closes Exclusive Worldwide License for HCW11-006 - A High Potential Fusion Immunotherapeutic | 1 | GlobeNewswire (USA) | ||
| 16.03. | HCW Biologics' compound shows promise in CAR-T cell production | 5 | Investing.com | ||
| 16.03. | HCW Biologics Inc.: HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances | 529 | GlobeNewswire (Europe) | Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells manufactured... ► Artikel lesen | |
| 02.03. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.02. | HCW Biologics Inc.: HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules | 5 | GlobeNewswire (USA) |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,540 | -10,63 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik | EQS-News: Evotec SE
/ Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung
Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik... ► Artikel lesen | |
| MODERNA | 43,090 | -5,01 % | Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an | Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als offizielle Fälle bestätigt. Aus... ► Artikel lesen | |
| VALNEVA | 2,540 | -1,01 % | Valneva-Aktie vor Zahlen: Was ist am 13. Mai zu erwarten? | Die Aktie von Valneva bleibt auch nach der jüngsten Kapitalspritze unter Druck. Nachdem bereits in unserem vorherigen Artikel auf die begrenzten Erholungschancen hingewiesen wurde, bestätigt die aktuelle... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 19,000 | 0,00 % | Palatin Technologies: Lizenzvereinbarung treibt Umsatz im dritten Quartal an und beflügelt die Aktie | ||
| VIVOSIM LABS | 1,290 | -1,53 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | 0,00 % | XFRA GBY: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSANGAMO THERAP.INC.DL-... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,360 | +3,69 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,650 | -1,08 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| XOMA ROYALTY | 35,200 | -1,12 % | XOMA Royalty Corp - 10-Q, Quarterly Report | ||
| CELLECTAR BIOSCIENCES | 2,930 | 0,00 % | Cellectar Biosciences Q1 2026 Earnings Preview | ||
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech raises $4.2M through warrant exercise deal | ||
| NOVOCURE | 15,735 | +0,90 % | Novocure Reports First Quarter 2026 Financial Results | Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio
Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic... ► Artikel lesen | |
| PHARMING | 1,137 | +1,84 % | Pharming Group N.V.: Pharming Group reports first quarter 2026 financial results; on track for Joenja U.S. pediatric label expansion and launches in Japan and Europe in 2026 | First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly... ► Artikel lesen | |
| TRAWS PHARMA | 1,750 | 0,00 % | Traws Pharma, Inc.: Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections | NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,120 | 0,00 % | Moleculin Biotech, Inc.: Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits | Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier... ► Artikel lesen |
Das Unternehmen HCW BIOLOGICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,358 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.